Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 74 of 74 publications.

Qin L, Chen Y, Lesher B, Qifa L, Charbonneau C, Earnshaw SR, McDade CL, Mao N, Gao X. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected aspergillus invasive fungal infections in China. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A237.

Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.

Pletcher MJ, Pignone M, Earnshaw SR, McDade CL, Phillips KA, Auer R, Zablotska L, Greenland P. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2014 Mar 1;7(2):276-84. doi: 10.1161/CIRCOUTCOMES.113.000799

Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422

Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013 Oct;28(11):1483-91.

Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.

Barnes R, Earnshaw SR, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade CL. Economic comparison of empirical versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infection. Poster presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 2013.

Hicks K, Earnshaw S, McDade C, Shaw JW, Cifaldi MA. Benefit-risk analysis of adalimumab and alternative treatments for moderate to severe rheumatoid arthritis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A439-40.

Earnshaw SR, McDade C, Chapman AM, Jackson D, Schwamm L. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom. Clin Ther. 2012 Jul 1;34(7):1544-58.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis. 2012 Apr 1;12:101.

Earnshaw SR, McDade CL, Zanotti G, Farkouh R, Strutton D. Cost-effectiveness of 2+1 dosing of 13-valent pneumococcal conjugate vaccine compared with 2+1 dosing of 10-valent conjugate vaccine in preventing pneumococcal disease in Canada. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A275.

Kattan MW, Earnshaw SR, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011 Sep 1;9(5):305-15.

Earnshaw SR, Chirila C, McDade CL, Black L, Andriole GL. Cost-effectiveness of dutasteride as a chemoprevention in prostate cancer: rEDUCE within-trial analysis. Presented at the 2011 ISPOR 16th Annual International Meeting; May 2011.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011 Feb 14;171(3):218-25.

Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004

Earnshaw SR, Taylor TN, McDade CL. Pharmacoeconomics and the drug development process.. In: Yih Y, editors. Handbook of healthcare delivery systems. Boca Raton: FL. CRC Press; 2010.

Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.

Earnshaw S, Pignone M, Fendrick AM, Scheiman J, McDade C. Cost-effectiveness of proton pump inhibitors for prevention of gastrointestinal adverse events when using aspirin for primary cardiovascular prevention. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A166.

Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.

Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.

Patel PA, Zyczynski TM, Beard SM, Earnshaw SR, McDade CL, Zimovetz E. A European multicountry comparison of the cost-effectiveness of iodixanol versus iohexol based on the results of the NEPHRIC clinical trial. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.

Bell CF, McDade CL, Black L, Earnshaw SR, Kattan MW. Considerations for modeling the cost-effectiveness of preventative prostate cancer treatments. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada.

Zyczynski TM, Beard SM, Earnshaw SR, McDade CL. Cost-effectiveness analysis of the use of iodixanol compared to iohexol in the United Kingdom. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007.

Earnshaw SR, McDade CL, Mangel AW, Baran RW. Cost-effectiveness of lubiprostone in a managed care population with chronic idiopathic constipation. Poster presented at the 2007 ACG Annual Meeting; September 2007. [abstract] Am J Gastroenterol. 2007 Sep; 102(S2):S449-50.